Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Details of HER2amp CTC detection and characteristics (*) HER2/CEP17 number and ratio in the 17 detected HER2amp CTC were as follows: 3/1/3.0 for each of the 17 CTC.

From: Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

PatientStepNo. of CTC detected
(/7.5 ml)
No. of CTC with FISHNo. of HER2amp CTCHER2 and CEP17 for each HER2amp CTC
N CEP17N HER2HER2/CEP17 ratio
Patients screened with HER2amp CTC, with no further sample (not treated or not assessed)
03-020-1Screening921133.0
03-030-1Screening247611133.0
03-031-1Screening69281263.0
03-039-1Screening111191177.0
04-003-1Screening3081263.0
10-004-1Screening3921252.5
03-037-2Screening308515263.0
263.0
252.5
252.5
252.5
10-005-2Screening47592611010.0
11010.0
188.0
133.0
252.5
252.5
Patients screened with HER2amp CTC with sample during therapy
01-017-1Screening2272133.0
133.0
Cycle #2950   
Progression2290   
05-005-1Screening3272133.0
133.0
Cycle #21060   
05-006-2Screening17106133.0
133.0
133.0
133.0
133.0
133.0
Cycle #2573117(*) see caption
07-010-1Screening3971672155.0
284.0
Cycle #244521632105.0
3103.3
133.0
08-001-1Screening3551711133.0
Cycle #2136953166.0
263.0
133.0
Progression6654844133.0
133.0
133.0
252.5
08-002-1Screening2751072144.0
252.5
Cycle #2242705144.0
133.0
133.0
133.0
133.0
133.0